Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.
Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.
复制标题
DOI：
10.1097/jto.0b013e31826df166
复制
发表时间：
2012-12
期刊：
影响因子：
--
通讯作者：
J. Riess;J. Neal
中科院分区：
文献类型：
--
作者：
J. Riess;J. Neal
最近批准的许多非小细胞肺癌（NSCLC）治疗方法对非鳞状非小细胞肺癌具有优先活性，因此开发有效的鳞状细胞组织肿瘤靶向治疗是一个有前景的研究领域。盘状蛋白结构域受体2 （DDR2）突变在鳞状非小细胞肺癌中并不常见，但似乎比在腺癌中更为普遍。成纤维细胞生长因子受体（FGFR）信号通路包括22个FGF配体和4个FGF受体，在鳞状非小细胞肺癌中也经常扩增或突变。本文讨论了针对非小细胞肺癌中这些分子改变的小分子药物。
Many of the recently approved therapies in non–small-cell lung cancer (NSCLC) are preferentially active against nonsquamous NSCLC, so development of effective targeted therapies in squamous cell histology tumors is a promising area of investigation. Discoidin domain receptor 2 (DDR2) mutations occur infrequently in squamous NSCLC but seem to be more prevalent than in adenocarcinoma. The fibroblast growth factor receptor (FGFR) signaling pathway, comprising 22 FGF ligands and four FGF receptors, is also frequently amplified or mutated in squamous NSCLC. Small-molecule drugs that target these molecular alterations in NSCLC are discussed here.